Therapie des Lupus erythematodes und der Lupusnephritis – Immunsuppression und mehr

Andreas Schwarting

doi:10.1055/s-0033-1363353

Dialyse aktuell, Table of Contents

Dialyse aktuell 2013; 17(9): 482-488
DOI: 10.1055/s-0033-1363353

Nephrologie

Therapie des Lupus erythematodes und der Lupusnephritis – Immunsuppression und mehr

Therapy of lupus erythematosus and lupus nephritis – Immunosuppression and more

Andreas Schwarting

¹ACURA Rheumazentrum Rheinland-Pfalz, Bad Kreuznach (ärztlicher Direktor: Prof. Dr. Andreas Schwarting) Schwerpunkt Rheumatologie und klinische Immunologie, I. Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz (Leiter: Prof. Dr. Andreas Schwarting)

› Author Affiliations

Abstract

Bei der Therapie des systemischen Lupus erythematodes (SLE) ist zu unterscheiden, ob eine milde Verlaufsform oder eine schwere Organmanifestation vorliegt. Während die milderen SLE-Fälle symptomatisch mit NSAR, niedrig dosierten Glukokortikoiden und Hydroxychloroquin behandelt werden, ist der Einsatz von immunsuppressiven Medikamenten bei schwerer Organbeteiligung unumgänglich. Für die Induktionstherapie der Lupusnephritis steht neben Ciclophosphamid auch Mycophenolatmofetil zur Verfügung. Ein Ansprechen nach 3 bzw. 6 Monaten ist hierbei ein guter prognostischer Marker für das Langzeitüberleben. Für die remissionserhaltende Therapie kommen Azathioprin oder MMF in Kombination mit Hydroxychloroquin zum Einsatz. Die Einführung von Belimumab hat darüber hinaus als erstes Biologikum in der Therapie des aktiven SLE das Tor für zukünftige, spezifischere Therapieansätze geöffnet.

Treatment of systemic lupus erythematosus (SLE) is based on disease activity and organ manifestation. While patients with mild lupus such as arthralgia or skin manifestation will be symptomatically treated using NSAID, low-dose corticosteroids and hydroxychloroquin, there is a need for immunosuppressive agents in lupus patients with severe organ involvement such as diffuse proliferative lupus nephritis. Treatment response after 3 and 6 months respectively is a good prognostic marker for long-term survival. For maintenance therapy, azathioprin or MMF in combination with hydroxychloroquin will be used. The introduction of belimumab as the first biological in lupus therapy opens a window for future specifically targeted therapy.

Key words

lupus erythematosus - lupus nephritis - therapy - immunosuppression

Full Text

References

Literatur
1 Bertsias G, Ioannidis JP, Boletis J et al. Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195-205
2 Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997; 29: 193-199
3 Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-64
4 Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228
5 Appel GB, Contreras G, Dooley MA et al. Aspreva Lupus Management Study Group. J Am Soc Nephrol 2009; 20: 1103-1112
6 Walsh M, James M, Jayne D et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007; 2: 968-975
7 Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006; 8
8 Grootscholten C, Ligtenberg G, Hagen EC et al. Dutch Working Party on Systemic Lupus Erythematosus. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006; 70: 732-732
9 Korbet SM, Lewis EJ, Schwartz MM et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000; 35: 904-914
10 Austin 3rd HA, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009; 20: 901-911
11 Ginzler EM, Wofsy D, Isenberg D et al. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 2010; 2: 211-221
12 Bertsias G, Tektonidou M, Amoura Z et al. European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-1782
13 Furie R, Petri M, Zamani O et al. BLISS-76 Study Group. BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-3930
14 Ng KP, Cambridge G, Leandro MJ et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007; 66: 1259-1262
15 Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233